SynthesisWorld journal of urology2024
Impact of pre-transplant malignancy on outcomes in kidney transplant recipients: an updated meta-analysis with systematic review.
Synthesis in World journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Challenges and outcomes in pediatric and adult kidney transplantation.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKidney transplantation is the optimal therapy for end-stage renal disease, but pre-transplant malignancy (PTM) is a concern due to the increased risk of cancer recurrence with immunosuppression. While advancements in immunosuppression and cancer treatments have improved kidney recipient and graft survival, the impact of PTM on survival remains unclear and warrants comprehensive assessment.
methodsThis systematic review and meta-analysis followed PRISMA guidelines. Relevant studies were identified through searches in PubMed, EMBASE, and Cochrane Library from inception to 1st May 2024 for outcomes including all-cause mortality, cancer-specific mortality, graft survival, death-censored graft survival, and de novo malignancy.
resultsEighteen studies were included in meta-analyses for various outcomes. Kidney transplant recipients with PTM had significantly higher all-cause mortality {hazard ratio [HR] = 1.45 [95% confidence interval (CI) 1.19-1.78]}, cancer-specific mortality [HR = 2.66 (95% CI 1.50-4.72)], risk of post-transplant de novo malignancy [HR = 1.66 (95% CI 1.22-2.25)] and worse graft survival [HR = 1.13 (95% CI 1.05-1.21)] compared to those without PTM. However, there was no significant difference in death-censored graft survival [HR = 1.09 (95% CI 0.82-1.45)].
conclusionsKidney transplant recipients with PTM experienced an increased risk of all-cause mortality, cancer-specific mortality, graft loss, and post-transplant de novo malignancy compared to those without PTM. Careful assessment, focused screening, and tailored management protocols are necessary for this high-risk group of patients.
Indexed as
Identifiers
39621141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.